AbbVie Inc. $ABBV is Duncker Streett & Co. Inc.’s 5th Largest Position

Duncker Streett & Co. Inc. boosted its stake in AbbVie Inc. (NYSE:ABBV) by 3.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,644 shares of the company’s stock after acquiring an additional 2,632 shares during the period. AbbVie accounts for approximately 3.1% of Duncker Streett & Co. Inc.’s holdings, making the stock its 5th biggest holding. Duncker Streett & Co. Inc.’s holdings in AbbVie were worth $16,234,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Renasant Bank raised its holdings in AbbVie by 142.8% in the first quarter. Renasant Bank now owns 4,955 shares of the company’s stock worth $1,078,000 after purchasing an additional 2,914 shares in the last quarter. Aljian Capital Management LLC boosted its position in shares of AbbVie by 15.0% in the 1st quarter. Aljian Capital Management LLC now owns 7,000 shares of the company’s stock worth $1,522,000 after purchasing an additional 914 shares in the last quarter. Bank of Stockton boosted its position in shares of AbbVie by 1.8% in the 1st quarter. Bank of Stockton now owns 3,857 shares of the company’s stock worth $839,000 after purchasing an additional 69 shares in the last quarter. Evergreen Private Wealth LLC grew its stake in shares of AbbVie by 11.8% in the 1st quarter. Evergreen Private Wealth LLC now owns 1,055 shares of the company’s stock worth $229,000 after buying an additional 111 shares during the last quarter. Finally, Hoey Investments Inc. increased its position in AbbVie by 5.5% during the 1st quarter. Hoey Investments Inc. now owns 3,867 shares of the company’s stock valued at $841,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the topic of several analyst reports. Cantor Fitzgerald boosted their target price on AbbVie from $240.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday. Evercore set a $235.00 price target on AbbVie in a research report on Friday, May 15th. Guggenheim reissued a “buy” rating and set a $249.00 price objective on shares of AbbVie in a research report on Friday, May 1st. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.67.

AbbVie Stock Performance

ABBV opened at $254.71 on Wednesday. The stock has a market capitalization of $450.02 billion, a P/E ratio of 125.47, a P/E/G ratio of 0.84 and a beta of 0.30. The company’s 50-day simple moving average is $222.39 and its two-hundred day simple moving average is $220.69. AbbVie Inc. has a 52-week low of $184.63 and a 52-week high of $261.64.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period in the previous year, the business posted $2.46 earnings per share. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. Research analysts forecast that AbbVie Inc. will post 14.28 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 340.89%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved TEPKINLY (epcoritamab) plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma, making it the first and only bispecific-based therapy approved in Europe for this setting and expanding AbbVie’s oncology growth opportunity. Article Title
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 from $240 and reiterated an overweight rating, signaling continued analyst confidence in the stock’s outlook. Article Title
• Neutral Sentiment: Media coverage highlighted AbbVie as a high-yield dividend and “quality, low-stress” healthcare stock, which may support investor sentiment but does not change fundamentals. Article Title
• Negative Sentiment: AbbVie lowered its Q2 2026 EPS guidance to $3.57-$3.61 versus the consensus $3.77, suggesting earnings could come in below expectations. Article Title
• Negative Sentiment: The company also cut full-year 2026 EPS guidance to $13.91-$14.11, below the consensus estimate of $14.25, which may pressure the shares despite recent product wins. Article Title

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.